The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five

Over the past several weeks, we’ve talked about how collaborations among key opinion leaders, clinical investigators and pharmaceutical and biotechnology companies benefit the companies, the KOLs or clinical investigators, and patients. The foundation of these mutually-beneficial collaborations is the objective, methodical approach to understanding KOLs’ and clinical investigators’ skills and experiences.

Many methods promise to illuminate the strengths of KOLs and investigators; however, key hallmarks of the best approaches include the following attributes:
· An objective review of accomplishments and areas of focus, including, but not limited to, a KOL’s/clinical investigator’s involvement in patient care, academic pursuits, medical publishing, basic and clinical investigation and areas of expertise.
· A keen understanding of the KOL’s/clinical investigator’s goals for his or her practice as well as his or her desires for partnering with industry.
· Commitment to involving KOLs and clinical investigators in activities that closely match their skills, experiences, goals and desires.

Thought Leader Select’s methodology, known as “deep profiling,” coupled with our leadership team’s 70+ years of combined experience working in and with the pharmaceutical and biotechnology industries has enabled our company to build an impressive record of success with assisting pharma with KOL engagement and deployment strategies. Our work results in more mutually-beneficial collaborations, for KOLs, pharma, and patients alike.

For more information on Thought Leader Select and our exclusive deep profiling for pharma and biotech KOL engagement and deployment needs, contact Neil Mellor at 905-927-0114 or

More Posts

Technology is Getting Smarter

By Paul Meade, Patient Engagement Lead  It has become apparent that in order for a healthcare organization to succeed, they need to be able to


Send Us A Message